Exhibit 99.1
Press Release www.shire.com |  |
Holding(s) in Company
June 10, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG)
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii | Shire plc |
| 2 Reason for the notification(please tick the appropriate box or boxes): |
| An acquisition or disposal of voting rights | |
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |
| An event changing the breakdown of voting rights | X |
| Other (please specify): | |
3. Full name of person(s) subject to the
notification obligation: iii | Deutsche Bank AG |
4. Full name of shareholder(s)
(if different from 3.):iv | Deutsche Bank AG, London Branch |
5. Date of the transaction and date on
which the threshold is crossed or
reached:v | 07/06/2016 |
| 6. Date on which issuer notified: | 09/06/2016 |
7. Threshold(s) that is/are crossed or
reached:vi, vii | Below notifiable threshold |
| 8. Notified details: |
| A: Voting rights attached to sharesviii, ix |
Class/type of
shares
if possible using
the ISIN CODE
| Situation previous
to the triggering
transaction | Resulting situation after the triggering transaction |
Number
of
Shares | Number
of
Voting
Rights | Number
of shares | Number of voting
rights | % of voting rightsx |
| Direct | Directxi | Indirectxii | Direct | Indirect |
| JE00B2QKY057 | 28,378,378 | 28,378,378 | Below notifiable threshold | Below notifiable threshold | 0 | Below notifiable threshold | 0 |
| B: Qualifying Financial Instruments |
| Resulting situation after the triggering transaction |
Type of financial
instrument | Expiration
datexiii | Exercise/
Conversion Periodxiv | Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted. | % of voting
rights |
| | | |
|
| C: Financial Instruments with similar economic effect to Qualifying Financial Instrumentsxv, xvi |
| Resulting situation after the triggering transaction |
Type of financial
instrument | Exercise price | Expiration datexvii | Exercise/
Conversion periodxviii | Number of voting rights instrument refers to | % of voting rightsxix, xx |
| | | | | | Nominal | Delta |
| | |
| Total (A+B+C) |
| Number of voting rights | Percentage of voting rights |
| Below notifiable threshold | Below notifiable threshold |
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:xxi |
|
| |
| Proxy Voting: |
| 10. Name of the proxy holder: | |
11. Number of voting rights proxy holder will cease
to hold: | |
12. Date on which proxy holder will cease to hold
voting rights: | |
13. Additional information: |
|
| 14. Contact name: | Stacy Otieno |
| 15. Contact telephone number: | 02075476268 |
For further information please contact:
| Investor Relations | | |
| | | |
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
